Clinical Trial Detail

Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation

Complete title: A Randomized Phase II Study to Compare the Net Clinical Benefit of Cyclosporine and Sirolimus combined with MMF or Post-Transplant Cyclophosphamide as GVHD Prophylaxis after HLA-Matched or HLA-Mismatched Unrelated G-CSF Mobilized Blood Cell Transplantation using Nonmyeloablative or Reduced Intensity Conditioning for Patients with Hematologic Malignancies: A Multi-Center Trial

Research Study Number	9816
Principal Investigator	Masumi Ueda Oshima
Phase	II

Look up trial at NIH

Research Study Description

This randomized phase II trial includes a blood stem cell transplant from an unrelated donor to treat blood cancer. The treatment also includes chemotherapy drugs, but in lower doses than conventional (standard) stem cell transplants. The researchers will compare two different drug combinations used to reduce the risk of a common but serious complication called "graft versus host disease" (GVHD) following the transplant. Two drugs, cyclosporine (CSP) and sirolimus (SIR), will be combined with either mycophenolate mofetil (MMF) or post-transplant cyclophosphamide (PTCy). This part of the transplant procedure is the main research focus of the study.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above **

Other eligibility criteria may apply.

Research Study Number	9816
Contact	Seattle Cancer Care Alliance Intake Office
Telephone	800-804-8824 / 206-606-1024

Keywords: Leukemia, Acute Lymphoblastic (ALL); Leukemia, Acute Myeloid (AML); Leukemia, Chronic Lymphocytic (CLL); Hematologic Malignancies; Lymphoma, Hodgkin; Leukemia; Lymphoma; Lymphoproliferative Disorders; Pediatric Cancers, Miscellaneous; Multiple Myeloma (MM); Myelodysplastic Syndromes (MDS); Lymphoma, Non-Hodgkin (NHL); Leukemia, Myeloid; Leukemia, Lymphoid; Immunoproliferative Disorders; Hematopoietic Cell Transplantation (HCT); Myeloproliferative Disorders (MPD); Myelodysplastic-Myeloproliferative Diseases; Waldenstrom Macroglobulinemia; Lymphoma, Mantle-Cell; Lymphoma, B-Cell; Lymphoma, Small Lymphocytic (SLL); Leukemia, Prolymphocytic; Bone Marrow Diseases; Leukemia, Chronic Myelogenous; Neoplasms, Plasma Cell; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Immune System Diseases; Plasma Cell Myeloma; Hematologic Diseases

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

Talk to your health care providers first before making decisions about your health care.

Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

RSS feed

Last Modified, June 25, 2019